Treatment strategies for HCC are evolving rapidly, with immunotherapy combinations showing promising results in large phase 3 clinical trials. However, effectiveness in clinical practice can differ from efficacy in trials given differences in patient populations, provider expertise, and protocols. We have participated in real-world data and meta-analyses to evaluate their effectiveness and safety in clinical practice. This research is important to refine treatment pathways and assess long-term outcomes across diverse patient populations.
Parikh ND, Jones P, Salgia R, Bhan I, Grinspan L, Jou J, Zhou K, Jalal P, Rocoaro G, Rangnekar A, Benhammou J, Pillai A, Mehta N, Wedd J, Yang JD, Kim A, Duarte-Rojo A, Oloruntoba O, Tevar A, Au J, Blain Y, Rao S, Furtado F, Catalano O, Lewis S, Mendiratta-Lala M, Kink K, Sachdev L, Lee E, Bruno J, Kamel I, Tolosa C, Kao K, Badawi T, Przybyszewski E, Nathani P, Quirk L, Hadel B, Leven E, Wong N, AlbertaianR, Chen A, Aloor F, Mohamed I, Elkheshen A, Marvil C, Issac G, Clinton J, Woo S, Yum J, Rieger E, Hutchinson A, Rieger E, Turner D, Alsudaney M, Hernandez P, Xu Z, Khalid A, Barrick B, Wang B, Tapper E, Hao W, Singal AG. Development and validation of a noninvasive model for the prediction of high-risk esophgaeal varices in patients with unresectable hepatocellular carcinoma. Clinical Gastroenterology and Hepatology 2025; 23(2): 281-290